Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
November 2019—Memorial Sloan Kettering Cancer Center announced that the New York State Department of Health has issued an approval for its Analysis of Circulating cfDNA to Evaluate Somatic Status (MSK-ACCESS) molecular assay. MSK-ACCESS was developed in the Marie-Josée and Henry R. Kravis Center for Molecular Oncology and has been clinically validated and implemented by members of MSK’s molecular diagnostics service.
November 2019—The Centers for Medicare and Medicaid Services granted approval for a new technology add-on payment (NTAP) to T2 Biosystems’ T2Bacteria Panel, for fiscal year 2020. The T2Bacteria Panel is the first in vitro diagnostic test to receive approval for NTAP, according to the company.
November 2019—Agilent Technologies introduced its xCELLigence RTCA eSight multimode real-time cell analyzer. The research use only system provides label-free, real-time biosensor measurements and kinetic imaging of the same live cell populations independently or simultaneously.
November 2019—MicroMedicine introduced Sorterra, an automated, microfluidics-based cell isolation and concentration system for research and development and clinical research labs. Sorterra isolates white blood cells from 3 to 75 mL of anticoagulated peripheral blood at a rate of 150 mL per hour.
November 2019—The FDA granted in October marketing authorization of the OraQuick Ebola Rapid Antigen Test to OraSure Technologies. The test is intended for use in patients suspected of and with signs or symptoms consistent with Ebola virus disease and when the patient meets the CDC’s Ebola virus epidemiological criteria, such as history of residence in or travel to a geographic region with active EVD transmission at the time of travel.
November 2019—The FDA has cleared iCubate’s iC-GN Assay for the detection and identification of Gram-negative bacteria that are associated with bloodstream infection and subsequent sepsis.
November 2019—Bio SB has introduced its TintoDetector Mini Immuno staining system for immunohistochemical, immunocytochemistry, and immunofluorescence protocols in a semiautomated, open platform.
November 2019—Sysmex Corporation has obtained Japanese manufacturing and marketing approval for the OncoBeam RAS CRC Kit, used for blood-based circulating tumor DNA molecular testing of mutations in the RAS gene for advanced colorectal cancer patients.
October 2019—The Project Santa Fe Foundation, which developed the concept of Clinical Lab 2.0, announced that it has filed for nonprofit 501c status and expanded its board of directors. New members of the board include health care leaders from Seattle Children’s Hospital, Intermountain Healthcare, University of Vermont, Mayo Clinic, and NorthShore University HealthSystem. “It is by design that PSFF did not trademark Clinical Lab 2.0, as we strongly believe that Clinical Lab 2.0 belongs to the health care industry, not to a single entity, and fundamentally believe that Clinical Lab 2.0 has no borders,” Khosrow Shotorbani, MBA, MT(ASCP), president and executive director of the Project Santa Fe Foundation, said in a press release. “The transition to value-based, Clinical Lab 2.0 standards will require cross-industry collaboration. We are honored to have these highly respected industry leaders join the global movement.” Project Santa Fe is a nonprofit organization founded through a collaboration of the Henry Ford Health System, Northwell Health, Geisinger Health System, and TriCore Reference Laboratories.
October 2019—The Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma. Pembrolizumab was approved for use in combination with platinum and fluorouracil for all patients and as a single agent for patients whose tumors express PD‑L1 (combined positive score, ≥1) as determined by an FDA‑approved test.
